国家神经系统疾病临床医学研究中心数据管理与共享系统
Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorder
第一作者：Yuzhen Wei
基本信息
- 负责人：Yuzhen Wei
- 数据来源： OTHERS
- 论文编号：OTHERS20190049
- 发表时间：2018-10-22
2018-10-22
已发表文章
发表杂志：BioMed Research International
发表类型: Original Contributions
影响因子(IF): 3.411
PMID: 30426010 Pubmed原文链接 全文下载
主要研究背景及目的
Astrocytic impairment is a pathologic feature of neuromyelitis optica spectrum disorder (NMOSD). S100B and glial fbrillary acidic protein (GFAP) are the two most commonly used astrocytic markers. Te aim of this study was to evaluate whether CSF-S100B could serve as a marker of NMOSD.
方法
We enrolled 49 NMOSD patients [25 aquaporin-4 antibody (AQP4-Ab)–positive, 8 myelinoligodendrocyte glycoprotein antibody (MOG-Ab)-positive, and 16 seronegative patients], 12 multiple sclerosis (MS) patients, and 15 other noninfammatory neurological diseases (OND) patients. Te CSF levels of S100B and GFAP were measured by ELISA.
结论
CSF-S100B might be a potential candidate biomarker for NMOSD in discriminating, evaluating severity, and predicting disability.
主要结果
Both CSF-S100B and GFAP levels signifcantly discriminated NMOSD from MS [area under curve (AUC) = 0.839 and 0.850, respectively] and OND (AUC = 0.839 and 0.850, respectively). Te CSF-S100B levels diferentiated AQP4-Ab–positive NMOSD from MOGAb–positive NMOSD with higher accuracy than the CSF-GFAP levels (AUC=0.865 and 0.772, respectively). Te CSF-S100B levels also signifcantly discriminated MOG-Ab–positive patients from seronegative patients (AUC = 0.848). Both CSF-S100B and GFAP levels were correlated with the Expanded Disability Status Scale (EDSS) during remission. Only the CSF-S100B levels were correlated with the CSF WBC count and the EDSS during attack. Te levels of CSF-S100B seemed to have a longer lasting time than the levels of CSF-GFAP, which may beneft patients who present late.